AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06522100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Prednisone placebo
Description: After the perfusion of placebo, patients will take by oral Prednisone placebo once a day for the same duration as that required if the patient was in the investigational medicinal products group (1 month + progressive decrease).
Study NCT05024032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT05024032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT06248749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV iron
Description: Intravenous Iron supplement
Study NCT06172309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTQ1062
Description: tablet(s) PO
Study NCT06328335 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive rehabilitation training
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study NCT06328335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation training
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study NCT06328335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rise-bed Training
Description: gradually elevating the bed (head-up tilt) is one of the common methods to treat orthostatic hypotension. This treatment adjusts the patient's bed angle to gradually raise their body, promoting balanced blood distribution throughout the body and reducing orthostatic hypotension symptoms.~In head-up tilt treatment, the bed angle is usually gradually increased from a horizontal position, and the specific angle can be determined based on the patient's condition and tolerance. This treatment process is generally monitored and controlled by medical personnel to ensure safety and effectiveness.~The mechanism of head-up tilt treatment is to increase venous return by changing the body position and increasing the effect of gravity, thereby increasing cardiac preload, output, and blood pressure. This helps to reduce orthostatic hypotension symptoms such as dizziness, lightheadedness, and fatigue.
Study NCT04983446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foralumab
Description: Foralumab is a second generation fully human anti-CD3 antibody
Study NCT04983446 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be the vehicle for the foralumab nasal solution without active drug (25 mM sodium acetate/125 mM sodium chloride/0.02% polysorbate 80, pH 5.5 buffer).
Study NCT05442788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB0017 150mg or matching placebo
Description: Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
Study NCT05442788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB0017 300mg or matching placebo
Description: Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
Study NCT05442788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB0017 450mg or matching placebo
Description: Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
Study NCT06169059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JLP-2004
Description: administration of JLP-2004(COX-2 inhibitor)
Study NCT06169059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-2004
Description: administration of JLP-2004(COX-2 inhibitor)
Study NCT06169059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JC-013
Description: administration of JC-013(COX-2 inhibitor))
Study NCT06169059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JC-013
Description: administration of JC-013(COX-2 inhibitor))
Study NCT05411315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restricted-use of arterial catheter
Description: The investigator will restrict the use of arterial catheters unless exclusion criteria is met.
Study NCT05411315 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-use of arterial catheter
Description: The investigator will allow standard-use of arterial catheters
Study NCT05505617 — intervention group
Intervention type: OTHER
Intervention: Single-breath nitric oxide lung diffusing capacity measurements according to type of device in random order.
Description: Device: Jaeger Masterscreen TM (PFT Pro, Vyaire, Hoechberg, Germany)~Device: HypAir Medisoft (Medisoft, Dinant, Belgium)
Study NCT05868616 — intervention group
Intervention type: DEVICE
Intervention: Cardiac Resynchronization Therapy (CRT)
Description: Cardiac resynchronization therapy (CRT) is a modality of cardiac pacing used in patients with left ventricular (LV) systolic dysfunction and dyssynchronous ventricular activation that provides simultaneous or nearly simultaneous electrical activation of the LV and right ventricle (RV) via stimulation of the LV and RV (biventricular pacing) or LV alone.
Study NCT06030024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Magnetic pulses delivered to the Fz area of the brain in a low frequency (1 Hz) manner.
Study NCT04632836 — intervention group
Intervention type: OTHER
Intervention: quality of life questionnaires
Description: responses for quality of life questionnaires (WHOQOL-BREF questionnaire, study specific questionnaire, PSQI index, HADS scale)
Study NCT06073561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: learning curve of Underwater mucosectomy
Description: Patients will be submitted to underwater mucosectomy (U-EMR)
Study NCT06519474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theraband chest compression
Description: Chest compression applicated via a Red Theraband over the upper or lower chest region
Study NCT05606432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructor-led, one-on-one M2M exercise group
Description: Participants will attend 3 exercise sessions per week for 24 weeks. Each session will last 15 - 40 minutes. Increasing by 5 - 10 minutes each week. Each session will last from 25 to 50 minutes by increasing 5 to 10 minutes each week. The exercise program will focus on improving cardiorespiratory fitness using a series of movement patterns accompanied by music. The program will be tailored to individuals' abilities (e.g., use of arms only vs. truck movement together; slow vs. fast tempo music). The exercise will be prescribed at a moderate intensity level (working somewhat hard with increased heart rate and breathing rate). For the follow-up phase (weeks 25-36), participants will receive the recorded M2M exercise sessions between the M2M instructors and themselves to continue to exercise for the remaining 12 weeks.
Study NCT05606432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-guided control with pre-recorded standard exercise videos
Description: Participants will exercise for 36 weeks using pre-recorded exercise videos. The videos include warm-up, flexibility, muscular strength, aerobic endurance, balance, and cool-down.
Study NCT06519708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Patients will receive an ultrasound-guided erector spinae plane block with the injection of 30 ml bupivacaine 0.25% after induction of general anesthesia.
Study NCT06519708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: External Oblique Intercostal Plane Block
Description: Patients will receive an ultrasound-guided external oblique intercostal plan block Intraoperative with the injection of 30 ml bupivacaine 0.25% after induction of general anesthesia.
Study NCT05876000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corheart 6 Left Ventricular Assist System
Description: Implantation of left ventricular assist device for mechanical circulatory support
Study NCT06232304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEACH
Description: TEACH is a cognitive behavioral coping skills program. It consists of six one-hour weekly sessions that are conducted either in-person or remotely.
Study NCT05513534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: A standard yoga program will be provided using Hatha poses.
Study NCT05513534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-speed Resistance Training
Description: Each session will consist of three sets of 10 repetitions each with 1.5 to 2-minute rest periods between sets. Participants will be instructed to control the concentric and eccentric velocity of each exercise, with each phase lasting approximately two to three seconds
Study NCT06278714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: The subjects will perform deep inspirations against a threshold device with varying resistances
Study NCT06278714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The subjects will perform deep inspirations against a threshold device with varying resistances
Study NCT06041607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared meditation
Description: Meditation sessions between patients, carers and third parties~* 12 weekly 2-hour sessions,~* 2 half-day 3-hour retreats after the 9th session and at the end of the programme~* 3 monthly follow-up sessions (2h) in remote format (videoconference)
Study NCT06041607 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meditation with patients oly
Description: Meditation sessions between patients only~* 12 weekly 2-hour sessions,~* 2 half-day 3-hour retreats after the 9th session and at the end of the programme~* 3 monthly follow-up sessions (2h) in remote format (videoconference)
Study NCT04887129 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 RT-PCR test
Description: Participating individuals (students and employees) will be tested for COVID-19 (RT-PCR) using a specimen collected using a mid-turbinate swab.~This asymptomatic testing regime starts on or after (if scheduling testing requires this to begin on a different day) enrollment and is repeated every 5-14 days for up to 16 months . Anyone testing positive is followed up as described below for symptomatic individuals.~Those presenting with symptoms will be also tested for COVID-19 (RT-PCR). Those with negative test results will return to the asymptomatic testing protocol.~Students who test positive are retested then 3 days until two negative tests. Employees who test positive also be tested every 3 days until two negative tests.
Study NCT04887129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine Education Campaign
Description: Utilizing information from focus groups, the investigators will develop and deploy an educational campaign aimed at improving vaccine hesitancy and student health
Study NCT06256796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fresh frozen plasma
Description: repeated doses of fresh plasma over 3 days in organophosphate poisoned patients
Study NCT04932486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: Transcutaneous electrical stimulation of the upper airway muscles
Study NCT04944004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CogniPlus
Description: The CBCT programmes proposed in this study is called CogniPlus. This software package offers training of scientifically proven trainable cognitive functions. According to the user manual, the lifelike interactive system and its automatic adaptability to client's ability level made CogniPlus feasible in community settings.
Study NCT04944004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training As Usual (TAU)
Description: Training As Usual (TAU)
Study NCT05812911 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen
Description: Standard oxygen therapy administered through a Venturi mask allowing a fraction of inspired oxygen (FiO2) setting to maintain a peripheral oxygen saturation (SpO2) ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted.
Study NCT05812911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFNO
Description: The oxygen therapy will be administered in a semi-sitting position, with a setting of the FiO2 and the oxygen flow rate, to obtain a SpO2 ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted.
Study NCT05812911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIV
Description: Systematic application of NIV using two levels of pressure, pressure support (PS) + positive end-expiratory pressure (PEEP) provided using a dedicated NIV ventilator or a standard ICU ventilator with the  NIV module  through a facial mask. The FiO2 will be set to obtain a SpO2 ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted.
Study NCT05498714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG+lactulose
Description: On the day before colonoscopy , Patients took 50mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM. On the day of the procedure, patients took 50 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.
Study NCT05498714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSP＋lactulose
Description: On the day before colonoscopy , Patients took 50mL lactulose solution at 7:00 PM. And then Patients began to drink 150 mL of CSP at 8:00 PM ,followed by 2000ml of clarified liquid. On the day of the procedure, 4-6 hours before colonoscopy, patients took 50 mL lactulose solution and the remaining 150mL of CSP ,then followed by 750ml of clarified liquid .
Study NCT06170294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCR-MAGE-A4 T-Cells
Description: * Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~* MAGE-A4-directed T cell receptor-engineered T Cells
Study NCT00809952 — intervention group
Intervention type: PROCEDURE
Intervention: recombinant FSH
Study NCT04943653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: intraperitoneal paclitaxel~20mg/BSA(Body Surface Area), 40mg/BSA, 60mg/BSA (phase I)~recommended dose (phase II)
Study NCT04587427 — intervention group
Intervention type: DRUG
Intervention: Radium 223 dichloride (Xofigo, BAY88-8223)
Description: Prescribed by physicians.
Study NCT04767919 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Percutaneous Nephrolithotomy (sPCNL)
Description: Endoscopic stone procedure using a laser placed in the kidney through an 30 Fr access sheath following balloon dilation.
Study NCT04767919 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Percutaneous Nephrolithotomy (MIP)
Description: Endoscopic stone procedure using a laser placed in the kidney through an 18 Fr access sheath following either balloon dilation or dilation using a single step metal dilator.
Study NCT05611320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Awareness campaign - communications campaign
Description: How this concept would work in a full deployment:~1. Develop a set of images of healthy meals with local produce. The meals will be child-friendly and easy to prepare.~2. Develop educational content to accompany the images, on the importance of shopping for local produce, and seasonality (when to use what). Optionally work with farmer associations to inform the seasonal options.~3. Package the materials as posters and/or digital infographics. The materials include a link to the campaign website, which has more information about nutrition, local produce and recipes to inspire parents.~4. Partner with government agencies (e.g., ministry of health) to deploy the posters in local supermarkets, and in newspapers and on social media. Make the materials available to the farmer associations for their dissemination as well.
Study NCT05611320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online shopping
Description: Provide information on an online shopping site where the parents can shop for local produce online, and have it delivered to their homes, to disrupt their current ingredient-selection habits. Working backwards from a potential broad implementation, here we identify key risks along the path, and examine how to use the pilot to de-risk those areas.
Study NCT05465577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CC Links
Description: The CC Links intervention is built on a platform of interdisciplinary team-based science, which ensured that the financial navigator worked closely with other members of the healthcare team including oncologists, nurses, transplant coordinators, social workers, and case managers, to help enhance financial hardship screening and connect survivors and caregivers with financial assistance services.
Study NCT06035757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bridion 200 MG in 2 ML Injection
Description: Sugammadex is administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each reversal agent is determined with response to TOF or PTC.
Study NCT06035757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridostigmine Bromide 5 MG/ML
Description: Pyridostigmine is administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each reversal agent is determined with response to TOF.
Study NCT06246461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: The control group was treated with 2,500 mg/m2 capecitabine, with 2,000 mg/m2 capecitabine for the medium-dose group and 1,500 mg/m2 capecitabine for the low-dose group.
Study NCT06246461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: The control group was treated with 2,500 mg/m2 capecitabine, with 2,000 mg/m2 capecitabine for the medium-dose group and 1,500 mg/m2 capecitabine for the low-dose group.
Study NCT04876469 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Radiofrequency treatment of the lumbar dorsal root ganglion
Description: Using radiocontrast media or not for the pulsed radiofrequency treatment of the lumbar dorsal root ganglion
Study NCT05679258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX15
Description: A single dose (8 mg/kg) of HLX15 via intravenous infusion.
Study NCT05679258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-sourced DARZALEX®
Description: A single dose (8 mg/kg) of US-sourced DARZALEX® via intravenous infusion.
Study NCT05679258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CN-sourced DARZALEX®
Description: A single dose (8 mg/kg) of CN-sourced DARZALEX® via intravenous infusion.
Study NCT05679258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-sourced DARZALEX®
Description: A single dose (8 mg/kg) of EU-sourced DARZALEX® via intravenous infusion.
Study NCT04355039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg Days 1-21
Study NCT04355039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg Days 1, 8, 15 and 22
Study NCT04355039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB053914 50 mg bis in die (BID)
Description: Dose level 0: 50 mg BID
Study NCT04355039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB053914 65 mg BID
Description: Dose level 1: 65 mg BID
Study NCT04355039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB053914 80 mg BID
Description: Dose level 2: 80 mg BID
Study NCT05324852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Description: Midazolam, 5 mg, injectable solution in 5mg/ml, intranasal administration, atomize into nose with Mucosal Atomizer Device (MAD) 5mg(1ml) up each nostril , one time
Study NCT05324852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular loxapine
Description: Loxapine, 100mg, injectable solution in 50mg/2ml intramuscular, intra muscular administration, one time
Study NCT05196295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen
Description: Participants take either 1 (n=5), 3 (n=5) or 6 (n=5) capsules every day for one month.
Study NCT04367818 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri-anal local anaesthetic infiltration
Description: postoperative pain relieve, among pediatrics patient
Study NCT04367818 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal anaesthesia
Description: Regional anaesthesia for postoperative pain relieve, among pediatrics patient
Study NCT05711212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micellar solubilized Xanthohumol
Description: single administration of 4 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol
Study NCT05711212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single administration of 4 soft gelatine capsules containing only micelles